Royalty Pharma plc Overview
Valuation check: RPRX's P/E ratio is 23.71, below the Healthcare sector average of 27.28.
Get informed when a big investor buys or sells
+ Follow23.71
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Royalty Pharma plc (RPRX) currently reports a P/E ratio of 23.71. That is below the Healthcare sector average of 27.28. Use the charts on this page to explore Royalty Pharma plc's P/E ratio history and peer comparisons.
Royalty Pharma plc's P/E ratio of 23.71 is lower than the Healthcare sector average of 27.28. That is roughly 13.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Royalty Pharma plc's market price to a fundamental measure such as earnings, sales, or book value. At 23.71, RPRX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 23.71, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.28. From there, open related valuation or income-statement pages for Royalty Pharma plc, and consider following RPRX for alerts when major investors trade the stock.
Royalty Pharma plc is classified in the Healthcare sector. On P/E ratio, it currently shows 23.71 versus a sector average near 27.28. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RPRX with unrelated industries.
